Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00973362 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
A Phase 3 study of Human Papillomavirus Infection, sponsored by Gen-Probe, Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,896
- Enrollment target
- 17
- Study locations
NCT00973362 is a Phase 3 study of Human Papillomavirus Infection that has completed, run by Gen-Probe, Incorporated. The registered enrollment target is 12,896 participants, above the 560-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (2203% higher). The trial reports 17 study locations across 10 states.
The verdict
NCT00973362, a Phase 3 study of Human Papillomavirus Infection, has completed, sponsored by Gen-Probe, Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,896 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
Conditions Studied
Interventions
- DEVICE APTIMA HPV Assay
- DEVICE FDA-Approved HPV DNA Test
Study Locations (17)
California
- San Fernando Valley Research - Canoga Park
- Healthcare Partners of Monterey Park - Los Angeles
- Diverse Research Solutions - Oxnard
- REMEK - Pomona
- West Coast OB-Gyn - San Diego
- HealthCare Partners - Torrance
- Penninsula Research Associates - Torrance
Florida
- Community Medical Research of South Florida - Miami
- Insignia Clinical Research - Tampa
Arkansas
- NEA Clinic Women's Clinic - Jonesboro
Georgia
- Emory University School of Medicine - Atlanta
Indiana
- Indiana Univ. School of Medicine Dept of Pathology Wishard Health Sciences - Indianapolis
Michigan
- Saginaw Valley Medical Research - Saginaw
Missouri
- PPS Clinical - Chesterfield
Oklahoma
- Planned Parenthood of Eastern Arkansas and Oklahoma - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,896 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00973362
The ClinicalTrials.gov registry entry for NCT00973362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,896 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 560-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (2203% higher). The listed sponsor is Gen-Probe, Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 2 interventions - of which APTIMA HPV Assay is the first listed.
NCT00973362 reports 17 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00973362 about?
NCT00973362 is a clinical study titled "Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System". The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
What is the current status of trial NCT00973362?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,896 participants. The study started on 2008-03. Estimated completion is 2014-04.
What conditions does trial NCT00973362 study?
This clinical trial studies the following conditions: Human Papillomavirus Infection.
What interventions are being tested in trial NCT00973362?
The interventions under investigation include: APTIMA HPV Assay (DEVICE), FDA-Approved HPV DNA Test (DEVICE).
Who is sponsoring clinical trial NCT00973362?
This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00973362 being conducted?
This trial has 17 study locations across Arkansas, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
RECRUITING · NA
-
Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.